Antihypertensive drug: Difference between revisions

'''Antihypertensives''' are a class of [[medication|drugs]] that are used to treat [[hypertension]] (high blood pressure). Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as [[stroke]], heart failure, kidney failure and [[myocardial infarction]]. Evidence suggests that reduction of the [[blood pressure]] by 5 mmHg can decrease the risk of stroke by 34% and of [[ischaemic heart disease]] by 21%, and can reduce the likelihood of [[dementia]], [[heart failure]], and [[death|mortality]] from [[cardiovascular disease]]. There are many classes of antihypertensives, which lower blood pressure by different means. Among the most important and most widely used medications are [[thiazide diuretic]]s, [[calcium channel blocker]]s, [[ACE inhibitor]]s, [[angiotensin II receptor antagonist]]s (ARBs), and [[beta blocker]]s.

Which type of medication to use initially for hypertension has been the subject of several large studies and resulting national guidelines. The fundamental goal of treatment should be the prevention of the important [[clinical endpoint|endpoints]] of hypertension, such as heart attack, stroke and heart failure. Patient age, associated clinical conditions and end-organ damage also play a part in determining dosage and type of medication administered. The several classes of antihypertensives differ in side effect profiles, ability to prevent endpoints, and cost. The choice of more expensive agents, where cheaper ones would be equally effective, may have negative impacts on national healthcare budgets. As of 2018, the best available [[evidence-based medicine|evidence]] favors low-dose thiazide diuretics as the [[first-line treatment]] of choice for high blood pressure when drugs are necessary. Although clinical evidence shows calcium channel blockers and thiazide-type diuretics are preferred first-line treatments for most people (from both efficacy and cost points of view), an ACE inhibitor is recommended by [[NICE]] in the UK for those under 55 years old.

In the United States, the JNC8 (Eighth Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) recommends thiazide-type diuretics to be one of the first-line drug treatments for hypertension, either as monotherapy or in combination with [[calcium channel blockers]], [[ACE inhibitors]], or  [[angiotensin II receptor antagonists]].<ref name=JNC8 /> There are fixed-dose [[combination drugs]], such as [[ACE inhibitor and thiazide combination]]s. Despite thiazides being cheap and effective, they are not prescribed as often as some newer drugs. This is because they have been associated with increased risk of new-onset diabetes and as such are recommended for use in patients over 65, for whom the risk of new-onset diabetes is outweighed by the benefits of controlling systolic blood pressure. Another theory is that they are off-patent and thus rarely promoted by the drug industry.

Medications that are classified as potassium-sparing diuretics which block the epithelial sodium channel (ENaC), such as [[amiloride]] and [[triamterene]], are seldom prescribed as monotherapy. ENaC blocker medications need stronger public evidence for their blood pressure reducing effect.

[[Calcium channel blocker]]s block the entry of calcium into muscle cells in artery walls.

The 8th Joint National Committee (JNC-8) recommends calcium channel blockers to be a first-line treatment either as monotherapy or in combination with [[thiazide]]-type diuretics, [[ACE inhibitor]]s, or [[angiotensin II receptor antagonist]]s for all patients regardless of age or race.

The ratio of CCBs' anti-[[proteinuria]] effect, non-dihydropyridine to dihydropyridine was 30 to -2.

[[ACE inhibitor]]s inhibit the activity of [[angiotensin-converting enzyme]] (ACE), an enzyme responsible for the conversion of angiotensin I into [[angiotensin]] II, a potent [[vasoconstrictor]].

A systematic review of 63 trials with over 35,000 participants indicated ACE inhibitors significantly reduced doubling of serum creatinine levels compared to other drugs (ARBs, α blockers, β blockers, etc.), and the authors suggested this as a first line of defense.<ref name = "wu" /> The AASK trial showed that ACE inhibitors are more effective at slowing down the decline of [[kidney function]] compared to [[calcium channel blockers]] and [[beta blockers]]. As such, ACE inhibitors should be the drug treatment of choice for patients with [[chronic kidney disease]] regardless of race or diabetic status.

However, ACE inhibitors (and angiotensin II receptor antagonists) should not be a first-line treatment for black hypertensives without [[chronic kidney disease]].<ref name=JNC8 /> Results from the [[Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial|ALLHAT]] trial showed that [[thiazide]]-type diuretics and calcium channel blockers were both more effective as monotherapy in improving cardiovascular outcomes compared to ACE inhibitors for this subgroup.<ref name=allhat /> Furthermore, ACE inhibitors were less effective in reducing blood pressure and had a 51% higher risk of stroke in black hypertensives when used as initial therapy compared to a calcium channel blocker. There are fixed-dose [[combination drugs]], such as [[ACE inhibitor and thiazide combination]]s.

Notable side effects of ACE inhibitors include [[dry cough]], [[hyperkalemia|high blood levels of potassium]], fatigue, dizziness, headaches, loss of taste and a risk for [[angioedema]].

[[Angiotensin II receptor antagonist]]s work by [[receptor antagonist|antagonizing]] the activation of [[angiotensin receptor]]s.

In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.{{citation needed|date=July 2019}}

In the VALUE trial, the angiotensin II receptor blocker valsartan produced a statistically significant 19% (p=0.02) relative increase in the prespecified secondary end point of myocardial infarction (fatal and non-fatal) compared with [[amlodipine]].

The CHARM-alternative trial showed a significant +52% (p=0.025) increase in myocardial infarction with [[candesartan]] (versus placebo) despite a reduction in blood pressure.

As a consequence of AT1 blockade, ARBs increase angiotensin II levels several-fold above baseline by uncoupling a [[negative-feedback]] loop. Increased levels of circulating Angiotensin II result in unopposed stimulation of the AT2 receptors, which are, in addition upregulated. Recent data suggest that AT2 receptor stimulation may be less beneficial than previously proposed and may even be harmful under certain circumstances through mediation of growth promotion, fibrosis, and hypertrophy, as well as proatherogenic and proinflammatory effects.

ARBs happens to be the favorable alternative to ACE inhibitors if the hypertensive patients with the heart failure type of reduced ejection fraction treated with ACEis was intolerant of cough, [[angioedema]] other than [[hyperkalemia]] or [[chronic kidney disease]].

Although [[beta blocker]]s lower blood pressure, they do not have a positive benefit on endpoints as some other antihypertensives. In particular, beta-blockers are no longer recommended as first-line treatment due to relative adverse risk of stroke and new-onset of type 2 diabetes when compared to other medications,<ref name=nps02 /> while certain specific beta-blockers such as [[atenolol]] appear to be less useful in overall treatment of hypertension than several other agents. A systematic review of 63 trials with over 35,000 participants indicated β-blockers increased the risk of mortality, compared to other antihypertensive therapies. They do, however, have an important role in the prevention of heart attacks in people who have already had a heart attack. In the United Kingdom, the June 2006 "Hypertension: Management of Hypertension in Adults in Primary Care" guideline of the [[National Institute for Health and Clinical Excellence]], downgraded the role of beta-blockers due to their risk of provoking [[type 2 diabetes]].

Despite lowering blood pressure, [[alpha blocker]]s have significantly poorer endpoint outcomes than other antihypertensives, and are no longer recommended as a first-line choice in the treatment of hypertension.

[[Sodium nitroprusside]], a very potent, short-acting vasodilator, is most commonly used for the quick, temporary reduction of blood pressure in emergencies (such as [[malignant hypertension]] or [[aortic dissection]]).[[Hydralazine]] and its derivatives are also used in the treatment of severe hypertension, although they should be avoided in emergencies.<ref name=Varon/> They are no longer indicated as first-line therapy for high blood pressure due to side effects and safety concerns, but hydralazine remains a drug of choice in [[gestational hypertension]].

[[Renin]] comes one level higher than angiotensin converting enzyme (ACE) in the [[renin–angiotensin system]]. [[Renin inhibitor]]s can therefore effectively reduce hypertension. [[Aliskiren]] (developed by Novartis) is a [[renin inhibitor]] which has been approved by the U.S. FDA for the treatment of hypertension.

Aldosterone receptor antagonists are not recommended as first-line agents for blood pressure, but spironolactone and eplerenone are both used in the treatment of [[heart failure]] and resistant hypertension.

[[Bosentan]] belongs to a new class of drugs and works by blocking [[endothelin]] receptors. It is specifically indicated only for the treatment of [[pulmonary artery]] hypertension in patients with moderate to severe heart failure.

Which type of many medications should be used initially for hypertension has been the subject of several large studies and various national guidelines. Considerations include factors such as age, race, and other medical conditions. In the United States, JNC8 (2014) recommends any drug from one of the four following classes to be a good choice as either initial therapy or as an add-on treatment: [[thiazide]]-type diuretics, [[calcium channel blockers]], [[ACE inhibitors]], or [[angiotensin II receptor antagonists]].

The first large study to show a mortality benefit from antihypertensive treatment was the VA-NHLBI study, which found that chlorthalidone was effective. The largest study, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) in 2002, concluded that chlorthalidone, (a thiazide-like diuretic) was as effective as lisinopril (an angiotensin converting enzyme inhibitor) or amlodipine (a calcium channel blocker). (ALLHAT showed that doxazosin, an alpha-adrenergic receptor blocker, had a higher incidence of heart failure events, and the doxazosin arm of the study was stopped.)

A subsequent smaller study (ANBP2) did not show the slight advantages in thiazide diuretic outcomes observed in the ALLHAT study, and actually showed slightly better outcomes for ACE-inhibitors in older white male patients.

Thiazide diuretics are effective, recommended as the best first-line drug for hypertension, and are much more affordable than other therapies, yet they are not prescribed as often as some newer drugs. [[Chlorthalidone]] is the thiazide drug that is most strongly supported by the evidence as providing a mortality benefit; in the ALLHAT study, a chlorthalidone dose of 12.5&nbsp;mg was used, with titration up to 25&nbsp;mg for those subjects who did not achieve blood pressure control at 12.5&nbsp;mg. Chlorthalidone has repeatedly been found to have a stronger effect on lowering blood pressure than hydrochlorothiazide, and hydrochlorothiazide and chlorthalidone have a similar risk of hypokalemia and other adverse effects at the usual doses prescribed in routine clinical practice. Patients with an exaggerated hypokalemic response to a low dose of a thiazide diuretic should be suspected to have [[hyperaldosteronism]], a common cause of secondary hypertension.

Other medications have a role in treating hypertension. Adverse effects of thiazide diuretics include [[hypercholesterolemia]], and [[impaired glucose tolerance]] with increased risk of developing [[Diabetes mellitus type 2]]. The thiazide diuretics also deplete circulating potassium unless combined with a [[potassium-sparing diuretic]] or supplemental potassium. Some authors have challenged thiazides as first line treatment.

Current UK guidelines suggest starting patients over the age of 55 years and all those of African/Afrocaribbean ethnicity firstly on calcium channel blockers or thiazide diuretics, whilst younger patients of other [[ethnic group]]s should be started on ACE-inhibitors. Subsequently, if dual therapy is required to use ACE-inhibitor in combination with either a calcium channel blocker or a (thiazide) diuretic. Triple therapy is then of all three groups and should the need arise then to add in a fourth agent, to consider either a further diuretic (e.g. [[spironolactone]] or [[furosemide]]), an alpha-blocker or a beta-blocker. Prior to the demotion of beta-blockers as first line agents, the UK sequence of combination therapy used the first letter of the drug classes and was known as the "ABCD rule".

* Age and [[Multiple morbidities|multi-morbidity]] can affect the choice of medication, the target blood pressure and even whether to treat or not.

* [[Chronic kidney disease]]. ACE inhibitors or ARBs should be included in the treatment plan to improve kidney outcomes regardless of race or diabetic status.

* [[Dementia|Late-stage Dementia]] should consider [[Deprescribing]] antihypertensives, according to the [[Medication appropriateness tool for co‐morbid health conditions in dementia (MATCH-D) criteria|Medication Appropriateness Tool for Comorbid Health Conditions in Dementia (MATCH-D)]]

* [[Gout]] may be worsened by thiazide diuretics, while losartan reduces serum urate.

* [[Kidney stone]]s may be improved with the use of thiazide-type diuretics  

* [[Heart block]]. β-blockers and nondihydropyridine calcium channel blockers should not be used in patients with heart block greater than first degree. JNC8 does not recommend β-blockers as initial therapy for hypertension

* [[Heart failure]] may be worsened with nondihydropyridine calcium channel blockers, the alpha blocker doxazosin, and the alpha-2 agonists moxonidine and clonidine. On the other hand, β-blockers, diuretics, ACE inhibitors, angiotensin receptor blockers, and aldosterone receptor antagonists have been shown to improve outcome.

* [[Pregnancy]]. Although α-methyldopa is generally regarded as a first-line agent, labetalol and metoprolol are also acceptable. Atenolol has been associated with intrauterine growth retardation, as well as decreased placental growth and weight when prescribed during pregnancy.  ACE inhibitors and angiotensin II receptor blockers (ARBs) are contraindicated in women who are or who intend to become pregnant.

* [[Periodontal disease]] could mitigate the efficacy of antihypertensive drugs.

* Race. JNC8 guidelines particularly point out that when used as monotherapy, thiazide diuretics, and calcium channel blockers have been found to be more effective in reducing blood pressure in black hypertensives than β-blockers, ACE inhibitors, or ARBs.

The JNC8 guidelines indicate reasons to choose one drug over the others for certain individual patients.

Hypertensive disorders during pregnancy constitute a significant risk factor for maternal and fetal outcomes, necessitating antihypertensive treatment. However, current data concerning the safety of in utero exposure to antihypertensive medication are controversial. While some studies recommend the administration of certain agents, others underline the possible adverse effects on fetal development. In general, a-methyldopa, β-blockers and calcium channel blockers are the first or second treatment line for hypertension during pregnancy. However, ACEIs, ARBs and diuretics are mostly contraindicated, as the potential risk outweighs the benefits of their administration. Additionally, several drugs should be avoided, due to the lack of data regarding their safety. Women are often concerned about the safety of antihypertensives and as a result, many do not take their treatment as prescribed. Shared decision-making aids have been shown to reduce women's uncertainty about taking antihypertensives and increase the number of women taking them as prescribed.

[[Chlorothiazide]] was discovered in 1957, but the first known instance of an effective antihypertensive treatment was in 1947 using [[Primaquine]], an antimalarial.

Vaccinations are being trialed and may become a treatment option for high blood pressure in the future. [[CYT006-AngQb]] was only moderately successful in studies, but similar vaccines are being investigated.

The latest evidence does not have evidence of an effect due to discontinuing vs continuing medications used for treating elevated blood pressure or prevention of heart disease in older adults on all-case mortality and incidence of heart attack. The findings are based on low quality evidence suggesting it may be safe to stop anti-hypertensive medications. However, older adults should not stop any of their medications without talking to a healthcare professional.